Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Will Unlisted AGs Rush for June Listing or Be Left on Ice?
With new pricing rules set to take effect in October that would put newly listed authorized generics (AGs) and biologic AGs on par with their originator products, the generic industry is increasingly viewing the upcoming June listing round as the…
To read the full story
Related Article
- Many Approved AGs Remain Unlisted Despite Final Pre-Reform Opportunity
June 12, 2026
- Challenges in a Post-AG Era: Ensuring a Reliable Supply System
April 6, 2026
- Espha Snags Bilanoa AG in Final Pre-Rule Approval Window
February 17, 2026
- Chuikyo OKs 3.5% Minimum NHI Price Hike, Sets Grace Period for New AG Pricing
January 19, 2026
- Gist of FY2026 Drug Pricing Reform Outline
December 26, 2025
- Chuikyo OKs FY2026 Drug Pricing Reform Outline, Scraps “Spillovers” but Adds New Follow-Up Rules
December 26, 2025
- AG Price Parity Plan Stokes Industry Fears of Patient, Pharmacy Defections
December 12, 2025
- MHLW Proposes Pricing New AGs and Bio-AGs on Par with Originators
December 4, 2025
- Japan Moves to Advance “G1” Price Cuts by 5 Years under Proposed LLP Overhaul
November 20, 2025
BUSINESS
- Taiho Takes Small-Molecule Expertise into ADCs; 3-Payload IND Due This Year
September 14, 2026
- Cuorips Raises 4 Billion Yen to Fund Post-Riheart Pipeline
September 14, 2026
- Boehringer, Medical Society Launch ILD Research Grant Program
September 14, 2026
- Otsuka Steps Up Neuroplastogen Push in Psychiatry
September 14, 2026
- Medipal, JCR Launch Global PI/II of MPS IIIB Therapy
September 14, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…